

Title (en)
METHODS OF THERAPY FOR NON-HODGKIN S LYMPHOMA

Title (de)
VERFAHREN ODER THERAPIE FÜR NICHT-HODGKIN-LYMPHOM

Title (fr)
METHODES THERAPEUTIQUES DE TRAITEMENT D'UN LYMPHOME NON HODGKINIEN

Publication
EP 1463524 A4 20050209 (EN)

Application
EP 02797231 A 20021206

Priority
• US 0239253 W 20021206
• US 1796801 A 20011207
• US 29366402 A 20021112

Abstract (en)
[origin: WO03049694A2] Methods for treating a human with lymphoma using a combination of interleukin-2 and at least one anti-CD20 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing IL-2, the other containing at least one anti-CD20 antibody, according to a dosing regimen. Administering of these two therapeutic agents together potentiates the effectiveness of either agent alone, resulting in a positive therapeutic response that is improved with respect to that observed with either agent alone. The therapeutic effects of these agents can be achieved using lower dosages of IL-2, thereby lessening the toxicity of prolonged IL-2 administration and the potential for tumor escape.
[origin: WO03049694A2] Methods for treating a human with lymphoma using a combination of interleukin-2 and at least one anti-CD20 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing IL-2, the other containing at least one anti-CD20 antibody, according to a dosing regimen. Administering of these two therapeutic agents together potentiates the effectiveness of either agent alone, resulting in a positive therapeutic response that is improved with respect to that observed with either agent alone. The therapeutic effects of these agents can be achieved using lower dosages of IL-2, thereby lessening the toxicity of prolonged IL-2 administration and the potential for tumor escape.

IPC 1-7
A61K 39/395; **A61K 38/20**; **A61P 35/00**

IPC 8 full level
A61K 38/00 (2006.01); **A61K 39/395** (2006.01); **A61P 7/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP)
A61K 39/39558 (2013.01); **A61P 7/00** (2017.12); **A61P 35/00** (2017.12); **C07K 16/2887** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/545** (2013.01); **C07K 2317/24** (2013.01)

Citation (search report)
• [XY] WO 0172333 A1 20011004 - CHIRON CORP [US], et al
• [X] YIRINEC B ET AL: "Preliminary report on biological effects of rituxan (R) and interleukin-2 (IL-2) in patients with low-grade or mantle cell non-Hodgkins lymphoma (NHL)", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 94, no. 10 suppl 1 part 2, 15 November 1999 (1999-11-15), pages 270b, XP002170813, ISSN: 0006-4971
• [X] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), THUMMALA ANURADHA R ET AL: "A Phase I/II study of Rituxan and interleukin 2 (IL-2) in patients with low grade or mantle cell non Hodgkins lymphoma (NHL): Preliminary results", XP001204186, Database accession no. PREV200200152443
• [Y] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2000 (2000-07-01), FEHNIGER T A ET AL: "Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.", XP001204064, Database accession no. NLM10880055
• [Y] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; August 1998 (1998-08-01), MEROPOL N J ET AL: "Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.", XP001204063, Database accession no. NLM9756416
• [A] JANAKIRAMAN N ET AL: "RITUXIMAB: CORRELATION BETWEEN EFFECTOR CELLS AND CLINICAL ACTIVITY IN NHL", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 10, SUP01 PT01, 15 November 1998 (1998-11-15), pages 337A, XP001009992, ISSN: 0006-4971
• [A] LEGET G A ET AL: "USE OF RITUXIMAB, THE NEW FDA-APPROVED ANTIBODY", CURRENT OPINION IN ONCOLOGY, CURRENT SCIENCE LTD, US, vol. 10, no. 6, November 1998 (1998-11-01), pages 548 - 551, XP000952702, ISSN: 1040-8746
• [PA] DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; June 2002 (2002-06-01), ATKINS M B: "Interleukin-2: Clinical applications", XP009041149, Database accession no. EMB-2002208050 & BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 2; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 250b, ISSN: 0006-4971 & THE JOURNAL OF CLINICAL INVESTIGATION, JUL 2000, vol. 106, no. 1, July 2000 (2000-07-01), pages 117 - 124, ISSN: 0021-9738 & CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII, AUG 1998, vol. 46, no. 6, August 1998 (1998-08-01), pages 318 - 326, ISSN: 0340-7004 & SEMINARS IN ONCOLOGY 2002 UNITED STATES, vol. 29, no. 3 SUPPL. 7, 2002, pages 12 - 17, ISSN: 0093-7754
• See references of WO 03049694A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)
WO 03049694 A2 20030619; **WO 03049694 A3 20031106**; AU 2002362098 A1 20030623; AU 2002362098 A8 20030623; CA 2469045 A1 20030619; EP 1463524 A2 20041006; EP 1463524 A4 20050209; JP 2005538034 A 20051215

DOCDB simple family (application)
US 0239253 W 20021206; AU 2002362098 A 20021206; CA 2469045 A 20021206; EP 02797231 A 20021206; JP 2003550745 A 20021206